JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Fludrocortisone acetate tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Indoco is comprehensively working on the remedial action plan
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Subscribe To Our Newsletter & Stay Updated